Researchers Call for Expansion of Mint Tobacco Ban

Dec.08.2022
Researchers Call for Expansion of Mint Tobacco Ban
Researchers urge FDA to expand ban on mint-flavored tobacco products to include potential substitutes like mint pipes and cigarillos.

Researchers from the Rutgers Tobacco Research Center and Ohio State University are calling for the US Food and Drug Administration (FDA) to expand the ban on mint-flavored cigarettes and cigars to include potential alternatives like mint-flavored pipes and rolling papers.


According to a study published in the journal Tobacco Control, researchers are urging the FDA to maximize the benefits of the ban on menthol-flavored cigarettes based on new evidence showing that these alternatives are attractive and have the potential to be addictive for adults who smoke menthol cigarettes.


Andrea Villanti, Associate Director of the Rutgers University Tobacco Research Center, stated that tobacco companies have renamed their roll-your-own tobacco as pipe tobacco to avoid taxes, and have branded flavored cigarettes as flavored cigars to evade federal bans. Villanti, the lead researcher of the study, said, "We have seen companies promoting pipe tobacco and cigarillos alongside cigarettes and filtered cigars. The products we tested in our research are likely the ones tobacco companies will promote after mint-flavored cigarettes are banned.


Researchers examined 98 adults who smoked menthol cigarettes to compare the addictive potential of combustible menthol with its substitutes. The study was conducted in four parts over a three-week period, during which participants first smoked their usual brand of menthol cigarettes. In the next three sessions, participants were randomly assigned three different menthol cigarette substitutes:


One cigarette that does not contain menthol alcohol is a pre-assembled menthol cigarette made with mint tobacco and a menthol pipe for filtering. It also includes a small menthol cigar.


During each meeting, researchers measured the smoking habits of participants, including the amount of carbon monoxide emitted, cravings, and withdrawal symptoms. Participants also self-reported their perceived effects of the drug and evaluated other measures of addiction potential for each product.


The team discovered that while menthol-filtered small cigars and non-mentholated cigarettes are attractive alternatives to menthol cigarettes, menthol pipe tobacco and rolling papers are the most alluring and lead to the highest number of indicators for future nicotine addiction. However, these products have not been considered for inclusion in the proposed ban.


According to the investigation results, the components of menthol cigarette products, including menthol paper, cigarette tube, and tobacco for pipe, should be included in the standards for menthol cigarettes and flavored cigars, as stated by Villanti.


Previous research has established a correlation between the use of menthol-flavored cigarettes and an increase in smoking initiation, nicotine dependence, and reduced adult smoking cessation, particularly among vulnerable populations. The FDA has proposed a regulation prohibiting the use of menthol as a flavoring agent in cigarettes and cigars to address this public health concern. Following a review of public feedback, a final decision is expected to be made in the coming months.


Currently, research results indicate that the components of menthol cigarette products, including menthol cigarette paper, filters, and tobacco, should be included in the standards for menthol cigarettes and flavored cigars," said Theodore Wagener, director of the center. The research was conducted by the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and the lead author of the study. "Failing to comply with this restriction would result in a serious loophole that the tobacco industry has already exploited and could potentially weaken the potential public health benefits of the proposed menthol ban.


2FIRSTS will continue to provide ongoing coverage of this topic, with further updates available on the "2FIRSTSAPP" platform. Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
French Vape Market Under Pressure as Europe’s First Listed Vape Company Kumulus Vape Reports 7.8% H1 Revenue Decline, Retail Sales Rise 41.5%
Kumulus Vape, Europe’s first publicly listed vape company, reported a 7.8% year-on-year decline in first-half 2026 revenue. Amid changing conditions in France’s vape market, the company said channel diversification helped offset pressure, with physical store sales increasing 41.5% year on year. Listed on Euronext Access Paris in 2019 and later transferred to Euronext Growth Paris, Kumulus Vape is viewed as a representative company of Europe’s vape sector. Its performance highlights the industry’s shift from rapid expansion toward more operationally focused growth.
Jul.27
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
2Firsts Data | China’s U.S. Vape Exports Have Yet to Regain Previous Growth Momentum in H1 2026, but Hardware Grew 15.2% and 6-Methyl Nicotine-Related Products Rose 234.7%
2Firsts Data | China’s U.S. Vape Exports Have Yet to Regain Previous Growth Momentum in H1 2026, but Hardware Grew 15.2% and 6-Methyl Nicotine-Related Products Rose 234.7%
China’s vape exports to the U.S. reached approximately $1.58 billion in the first half of 2026, remaining broadly stable from a year earlier but still below previous growth momentum. 2Firsts’ analysis of China Customs data shows that the U.S. market has not simply returned to its previous trajectory after the enforcement shock and inventory-driven swings of 2025. Instead, export momentum is shifting across product categories. Vaping devices and atomization hardware increased 15.2% year over year, while 6-methyl nicotine-related and other nicotine substitute products surged 234.7%. Meanwhile, traditional nicotine-containing vaping products continued to face pressure.
Jul.22
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs data showed that illegal cigarettes and vape products seized during the first seven months of 2026 were valued at about PHP11.68 billion, exceeding the PHP2.516 billion recorded for the full year of 2025. The figures were disclosed by a Bureau of Customs official during a House Committee on Ways and Means hearing on tobacco excise tax reforms. Vape-related seizures were valued at about PHP1.65 billion, with most cases recorded at the Manila International Container Port. Customs officials said enforcement against illicit tobacco trade would continue.
Aug.26
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
Product | IVG Launches NEXiO Prefilled Pod System, Expanding Beyond Disposable Vapes
UK vape brand IVG has launched the NEXiO reusable prefilled pod system, expanding its product portfolio beyond disposable vape products. The device features a 1,000mAh rechargeable battery, prefilled pods with a refill reservoir structure and a claimed capacity of up to 10,000 puffs. Officially launched in the UK on July 9, 2026, NEXiO debuted with 17 flavor options, reflecting IVG’s move into reusable pod formats.
Aug.19